NEWS
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Lexaria Bioscience Corp. (Nasdaq: LEXX) reports positive interim results from its diabetes animal study WEIGHT-A24-1. After 28 days of dosing, DehydraTECH-processed drug therapies showed decreased body weight gain or weight reduction. Key findings include:
1. DehydraTECH-CBD formulation 3 and DehydraTECH-liraglutide produced the largest weight loss: -1.50% and -1.58% respectively.
2. DehydraTECH appears effective with both semaglutide and liraglutide.
3. DehydraTECH-processed pure semaglutide performed similarly to reformulated Rybelsus® with SNAC technology.
4. Dosing for the final four study arms has begun, including combinations of DehydraTECH-processed drugs.
The study aims to explore potential enhancements in brain absorption and glucose control. Full results, including blood glucose and pharmacokinetic data, are pending.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment